Roche to invest another CHF 1.2 billion in upgrading the Basel site

2023-11-17

Clear commitment to Switzerland as a location for research and production
Investments in another research building, renewal of chemical production and the Institute of Human Biology
Modernisation of research and production infrastructure

Basel, 17 November 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced plans to further renew its infrastructure at the Basel site. Over the next few years, Roche will invest CHF 1.2 billion in another research and development building, the renewal of the synthetic chemical molecule production and a building for the Institute of Human Biology. CHF 3 billion have been invested in the site since 2014.

Jürg Erismann, Head of the Basel/Kaiseraugst Site, comments: “The investment of another CHF 1.2 billion is an important step for the future of the Basel site. The new buildings will expand the infrastructure for future innovations along the entire pharmaceutical value chain, from research to production. This is another clear commitment to the Basel research and production site and to Switzerland.”

The planned investments of CHF 1.2 billion include the following projects:

Building 12 / research and development building

To serve as an important link between research and development departments in the global Roche network
72 metres high with 13 storeys
State of art laboratory workstations for up to 450 researchers
Total investment of around CHF 500 million

Building 50 and 51 / synthetic and chemical production

New production building for manufacturing synthetic medicines. This is an area in which Roche has a broad pipeline of new active substances
Replacement of existing site infrastructure with new Building 51 and refurbishment and expansion of existing Building 50
Total investment of around CHF 570 million

Building 92 / Institute of Human Biology

Development of innovative organoids to improve the understanding of diseases and develop treatments
Space for up to 250 researchers of the Institute of Human Biology
The existing Building 92 will be completely rebuilt to adapt it to the needs of the institute
The building is also home to central laboratory services for research
Total investment of around CHF 100 million

The planned development will be realised within the framework of the existing building plan for the northern part of the site. We expect the construction of the research building and the building renovations to be completed by 2030.

Renderings, facts and figures and a film about site development are available at www.roche.ch

You can find more information about the Institute of Human Biology here.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Global Media Relations

Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD Phone: +41 79 407 72 58	Nathalie Altermatt Phone: +41 79 771 05 25
Simon Goldsborough Phone: +44 797 32 72 915	Karsten Kleine Phone: +41 79 461 86 83
Nina Mählitz Phone: +41 79 327 54 74	Kirti Pandey Phone: +49 172 6367262
Rebekka Schnell Phone: +41 79 205 27 03	Sileia Urech Phone: +41 79 935 81 48